Why Isn't IVUS Used More Often?

Introduction

The evidence supporting IVUS-guided coronary intervention has grown steadily stronger over two decades. Meta-analyses consistently show reduced cardiac events, better stent results, and plausible mortality benefits. Yet IVUS remains underutilized in clinical practice. Most coronary interventions in the United States and many other countries are still performed with angiographic guidance alone.

This gap between evidence and practice raises important questions for patients. If IVUS improves outcomes, why isn’t every interventionalist using it? The answers involve economics, training, time constraints, institutional factors, and medical culture. Understanding these barriers helps patients appreciate why they may need to advocate for imaging that guidelines increasingly recommend. For the evidence supporting IVUS use, see the clinical trial summary and indications article.

What are the main barriers to broader IVUS adoption?

Multiple factors converge to limit IVUS utilization. Economics plays a central role, as discussed in the costs and insurance article. But financial considerations are only part of the story. Time pressure, training requirements, institutional culture, and even inertia all contribute to underuse.

Procedural time is a consistent barrier. Adding IVUS extends the catheterization procedure, reducing throughput in busy cath labs. This creates tension between optimal imaging and operational efficiency. Physicians under pressure to maintain case volume may skip imaging that adds time even when they believe it would help.

Training and comfort level also matter. Operators who trained before IVUS became widely available may be less fluent in its use and interpretation. Younger interventionalists exposed to intravascular imaging during fellowship may adopt it more readily. This generational transition takes time to work through the profession.

How does reimbursement structure affect IVUS utilization?

Reimbursement for IVUS often does not fully compensate for the catheter cost and additional time required. When a procedure loses money or barely breaks even, hospitals discourage it regardless of clinical benefit. This economic pressure operates at the institutional level, influencing what resources are available and what behaviors are encouraged.

The fee-for-service payment model creates perverse incentives. Doing more procedures generates more revenue, while taking more time per procedure reduces revenue potential. IVUS, which takes time but may prevent future events, fits poorly into this model. The long-term savings from avoided complications accrue to insurers and patients, not to the hospitals and physicians incurring the upfront costs.

Value-based payment models that reward outcomes rather than volume could theoretically favor IVUS adoption. If hospitals were paid based on patient outcomes rather than procedure counts, the calculus would shift. Such payment reforms are gradually emerging but remain far from universal.

Does IVUS add significant procedural time, and does that matter?

IVUS typically adds 10-20 minutes to a coronary intervention. This may not sound like much, but in a high-volume cath lab performing 5-10 cases per day, cumulative time adds up. One additional case per day represents significant revenue. The opportunity cost of IVUS time is real even if not explicitly calculated.

Time pressure affects physician behavior in ways that are not always conscious. When running behind schedule, operators naturally look for steps to omit. IVUS, being add-on imaging rather than the core procedure, becomes an easy target. The patient in the next case is waiting, the staff want to go home, and the imaging feels optional even when it would help.

The time argument cuts both ways. IVUS can actually save time by providing clarity about vessel sizing and plaque distribution upfront, avoiding trial-and-error with balloon and stent selection. A procedure that goes smoothly with good imaging may ultimately take less time than one complicated by undersized stents requiring revision. But this efficiency gain requires adopting IVUS as routine practice, not just occasional use.

What training is required for IVUS competency and is it a barrier?

IVUS interpretation requires specific training that not all interventional cardiologists received during fellowship. The images look different from angiograms and require understanding of ultrasound physics, artifact recognition, and measurement techniques. Developing this fluency takes time and supervised experience.

Contemporary interventional cardiology fellowships typically include intravascular imaging training. But physicians who completed training before IVUS became standard may have less exposure. Continuing medical education courses offer catch-up training, but weekend courses cannot replicate years of fellowship experience with routine imaging use.

The learning curve creates a chicken-and-egg problem. Operators who rarely use IVUS feel less comfortable with it and therefore avoid it. This avoidance prevents them from developing proficiency, perpetuating discomfort. Breaking this cycle requires institutional commitment to making IVUS routine rather than exceptional.

How does IVUS utilization vary by hospital type (academic vs community)?

Academic medical centers generally use IVUS more frequently than community hospitals. The teaching mission at academic centers supports taking additional time for imaging. Fellowship programs require case exposure to intravascular imaging. Research activities may also favor imaging that generates publishable data.

Community hospitals face more direct throughput pressure. Without the educational mission to justify longer procedures, the purely economic calculus dominates. Smaller programs may not have IVUS equipment available at all, or may reserve it for selected complex cases rather than routine use.

Geographic variation in IVUS use is substantial within the United States and dramatic internationally. Japan and Korea use IVUS in the majority of coronary interventions. The United States lags significantly, with IVUS used in perhaps 15-30% of cases depending on region and institution. Europe falls somewhere between. These international differences cannot be explained by patient populations or disease patterns.

How does IVUS use in the US compare to other countries?

Asian countries, particularly Japan and South Korea, lead the world in IVUS utilization. Studies consistently report IVUS use rates exceeding 70-80% of coronary interventions in these countries (Zhang et al., 2018). Japanese guidelines explicitly recommend intravascular imaging more strongly than American guidelines, and reimbursement structures may be more favorable.

The reasons for this international variation are debated. Cultural factors, training traditions, and healthcare system differences all likely contribute. Japanese cardiologists may simply expect to use imaging as part of standard practice, while American cardiologists treat it as optional adjunct. These cultural differences are embedded in training programs and reinforced by practice patterns.

For American patients, the international comparison provides useful context. If excellent outcomes are achievable with routine IVUS use in Asia, American underutilization represents a gap that could theoretically be closed. The barriers are not technological or scientific but rather organizational and cultural.

Do interventional cardiologists have incentives for or against IVUS use?

Incentives for individual physicians are complex and vary by practice setting. Employed physicians may be evaluated partly on productivity metrics that IVUS-driven time extension would negatively affect. Physicians in private practice may balance patient care priorities against schedule efficiency differently.

Some operators genuinely believe that IVUS adds little value for most cases. They point to their own good outcomes with angiographic guidance and question whether imaging would have changed their decisions. This confidence may be appropriate for truly straightforward cases but becomes problematic when applied broadly to all patients.

Medico-legal considerations create some incentive for IVUS use. If a stent-related complication occurs and IVUS was not used, the operator might face questions about why available imaging was omitted. This defensive medicine consideration pushes toward more imaging. But it operates as a background factor rather than a primary driver of practice patterns.

What would need to change for IVUS to become standard of care?

Guideline recommendations have gradually strengthened toward routine intravascular imaging for PCI. Moving IVUS from Class II (reasonable to consider) to Class I (recommended) for broader indications would send a clearer signal. Professional societies have the authority to make such changes as evidence accumulates.

Reimbursement reform would address economic barriers more directly. If IVUS-guided PCI were reimbursed at a premium reflecting its better outcomes, the financial calculus would shift. Bundled payment models that reward results rather than volume could similarly favor imaging that prevents complications.

Perhaps most importantly, culture change within interventional cardiology would need to make imaging the default expectation rather than an exception. This requires leadership from training program directors, professional societies, and influential practitioners. The transition is underway but incomplete, and patients should understand that current practice does not yet reflect best evidence.

Conclusion

The gap between IVUS evidence and utilization reflects systemic healthcare challenges that extend far beyond any single technology. Economic incentives, time pressure, training variations, and institutional factors all contribute. Individual patients cannot solve these systemic problems, but they can work within them more effectively by understanding the dynamics.

Patients who want IVUS can advocate for it by choosing facilities and physicians known for advanced imaging capabilities. They can ask questions about imaging plans before procedures. They can verify insurance coverage and reduce financial barriers where possible. These individual actions do not change the system but can improve individual outcomes within it.

The broader trajectory favors increased IVUS use. Evidence continues to accumulate, guidelines are strengthening, and younger cardiologists are more comfortable with imaging. The question is not whether IVUS will become more routine, but how quickly. Patients advocating for themselves accelerate this transition while protecting their own interests during the period when underutilization persists.